Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer

Huang,Chao-You; Han,Zheng; Li,Xi; Xie,Hui-Hua; Zhu,Shan-Shan

doi:10.3892/ol.2017.6641

Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer

Authors:
- Chao-You Huang
- Zheng Han
- Xi Li
- Hui-Hua Xie
- Shan-Shan Zhu
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, Hexian Memorial Hospital of Panyu, Guangzhou, Guangdong 511400, P.R. China, Department of Breast and Thyroid Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: July 20, 2017 https://doi.org/10.3892/ol.2017.6641
Pages: 3623-3627
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of epigallocatechin‑3-gallate (EGCG) on the apoptosis of the human MCF-7 cancer cell line and the underlying mechanism. MCF-7 cells were divided into the control group and EGCG groups. The proliferation of MCF-7 cells in the two groups was determined using MTT and apoptosis was examined using flow cytometry. Western blot analysis and qRT-PCR were used to analyze P53 and Bcl-2 expression levels. The silencing effect of specific siRNA was evaluated using RT-PCR and western blot analysis. P53 and Bcl-2 expression levels were determined using western blot analysis in the si-P53, EGCG and EGCG‑combined si-P53 groups. EGCG inhibited the proliferation of MCF-7 cells in a concentration-dependent manner and IC50 was 37.681 mol/l. The apoptotic rates were 1.37 and 5.83% (t=8.9, p=0.0124) in the blank control and treatment groups after treatment with 30 µmol/l EGCG. The RT-qPCR and western blot results demonstrated that the effect of siRNA interference was evident. The expression of P53 in the EGCG‑combined si-P53 group was higher than that of the si-P53 group, but lower than the EGCG group. The Bcl-2 expression level in the EGCG‑combined si-P53 group was lower than that of the si-P53 group and higher than that of the EGCG group. In conclusion, EGCG suppressed the proliferation of human MCF-7 breast cancer cells and promoted apoptosis. In addition, the underlying mechanism may be related to the P53/Bcl-2 signaling pathway.

View Figures

View References

1	Yang CS and Wang ZY: Tea and cancer. J Natl Cancer Inst. 85:1038–1049. 1993. View Article : Google Scholar : PubMed/NCBI
2	Tan XH, Zhou DY and Zhang YL: Advances in research on anticancer mechanism of tea. Foreign Medical Oncology. 25:41998.
3	Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998. View Article : Google Scholar : PubMed/NCBI
4	Ahmad N, Feyes DK, Nieminen AL, Agarwal R and Mukhtar H: Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 89:1881–1886. 1997. View Article : Google Scholar : PubMed/NCBI
5	Zhang G, Wang Y, Zhang Y, Wan X, Li J, Liu K, Wang F, Liu K, Liu Q, Yang C, et al: Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med. 12:163–176. 2012. View Article : Google Scholar : PubMed/NCBI
6	Liang YC, Lin-Shiau SY, Chen CF and Lin JK: Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (−)-epigallocatechin-3-gallate. J Cell Biochem. 75:1–12. 1999. View Article : Google Scholar : PubMed/NCBI
7	Sartippour MR, Shao ZM, Heber D, Beatty P, Zhang L, Liu C, Ellis L, Liu W, Go VL and Brooks MN: Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr. 132:2307–2311. 2002.PubMed/NCBI
8	Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW and Weinstein IB: Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol. 2:350–359. 2002. View Article : Google Scholar : PubMed/NCBI
9	Farabegoli F, Papi A and Orlandi M: (−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 31:99–108. 2011. View Article : Google Scholar : PubMed/NCBI
10	Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
11	Pakos EE, Kyzas PA and Ioannidis JP: Prognostic significance for TP53 tumor suppressor gene expression and mutations in human motations in human osteosarcoma: A meta-analysis. Clin Cancer Res. 10:6208–6214. 2004. View Article : Google Scholar : PubMed/NCBI
12	Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol. 24:469–476. 1993. View Article : Google Scholar : PubMed/NCBI
13	Dastjerdi MN, Rarani MZ, Valiani A and Mahmoudieh M: The effect of adenosine A1 receptor agonist and antagonist on p53 and caspase 3, 8, and 9 expression and apoptosis rate in MCF-7 breast cancer cell line. Res Pharm Sci. 11:303–310. 2016. View Article : Google Scholar : PubMed/NCBI
14	Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J and Duffy MJ: Mutant p53: A novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer. 140:234–246. 2017. View Article : Google Scholar : PubMed/NCBI
15	Darb-Esfahani S, Denkert C, Stenzinger A, Salat C, Sinn B, Schem C, Endris V, Klare P, Schmitt W, Blohmer JU, et al: Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget. 7:67686–67698. 2016. View Article : Google Scholar : PubMed/NCBI
16	Schinzel A, Kaufmann T and Borner C: Bcl-2 family members: Integrators of survival and death signals in physiology and pathology. Biochim Biophys Acta. 1644:95–105. 2004. View Article : Google Scholar : PubMed/NCBI
17	Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P and Moll UM: p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
18	Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP and Zhang CH: (−)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J Gastroenterol. 13:1162–1169. 2007. View Article : Google Scholar : PubMed/NCBI
19	Qanungo S, Das M, Haldar S and Basu A: Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis. 26:958–967. 2005. View Article : Google Scholar : PubMed/NCBI